ArticleHIV medicine2026
Sustained effect of Scotland's HIV pre-exposure prophylaxis programme on transmission among gay and bisexual men who have sex with men: Population-based retrospective cohort study.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo evaluate the population-level impact of seven years of Scotland's HIV pre-exposure prophylaxis (PrEP) programme among gay, bisexual and other men who have sex with men (GBMSM).
methodsNational administrative data were used to estimate PrEP coverage and HIV incidence among 35 342 GBMSM attending specialist sexual health services between July 2015 and March 2024. Poisson regression was used to investigate the risk of HIV acquisition and its association with the extent of PrEP prescribing.
resultsPrEP coverage increased from 21% in the initial PrEP period (July 2017 to March 2020) to 45% in the latter period (April 2022 to March 2024). HIV incidence reduced from 4.46 per 1000 person-years in the pre-PrEP period (July 2015 to June 2017) to 1.66 in the initial PrEP period (aIRR 0.37, 95% CI 0.25-0.54) and remained stable thereafter. During the entire PrEP period, the risk of HIV acquisition was reduced among those 'currently prescribed' (involving 4 HIV acquisitions among 11 720 person-years) compared to those never prescribed (60 HIV acquisitions among 34 328 person-years) (aIRR 0.19, 95% CI 0.07-0.51). Compared to those currently prescribed PrEP, risk was greatest in those prescribed 12+ months ago (11 HIV acquisitions among 3824 person-years) (aIRR 8.13, 95% CI 2.58-25.64).
conclusionsHIV incidence was sustained at a low level as PrEP coverage broadened among GBMSM, but did not reduce further. Efforts to support persistence and re-engagement with PrEP are warranted in those at ongoing risk of HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.